FY22 results reflect a period dominated by Covid, where revenues more than doubled YoY as Yourgene moved quickly to capitalise on available opportunities. The world has since moved on, and we are highly encouraged to see a return to growth in the core business of 20%+ in Q1. Furthermore, this looks to be broadly based, with NIPT, DPYD and Ranger Tech all showing strong growth in the period. We make no material changes to our forecasts and continue to see a substantial growth opportunity ahead. W ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prelims in line, Q1 trading shows return of core growth
- Published:
27 Jul 2022 -
Author:
Chris Glasper -
Pages:
9
FY22 results reflect a period dominated by Covid, where revenues more than doubled YoY as Yourgene moved quickly to capitalise on available opportunities. The world has since moved on, and we are highly encouraged to see a return to growth in the core business of 20%+ in Q1. Furthermore, this looks to be broadly based, with NIPT, DPYD and Ranger Tech all showing strong growth in the period. We make no material changes to our forecasts and continue to see a substantial growth opportunity ahead. W ....